Vitamin D deficiency has been known for a long time to cause skeletal diseases such as rickets in children, and osteomalacia in adults.[@ref1] Apart from its importance in the management of osteoporosis, lately it was recognized that an association exists between vitamin D deficiency and many acute and chronic illnesses such as cancer, type 1 and type 2 diabetes mellitus, hypertension, cardiovascular diseases, infectious diseases, autoimmune diseases, and depression.[@ref2]-[@ref7] With the improved understanding of the risks of vitamin D deficiency, more attention for the evaluation of vitamin D status has been undertaken and the clinical demand for assessment of vitamin D status has rapidly increased. In general, measurement of 25-hydroxyvitamin D (25-OHD) level in serum or plasma is accepted as a reliable indicator of vitamin D status, but assay technology needs to be able to measure both D~2~ and D~3~ metabolites. Thresholds of serum 25-OHD concentration to define vitamin D deficiency are highly debated, but there is a consensus agreement that vitamin D sufficiency should be defined as 25-OHD level of \>75 nmol/L (\>30ng/ml), insufficiency as 50-75 nmol/L (20-30 ng/ml), and deficiency as \<50 nmol/L (\<20 ng/ml).[@ref8] These deficiencies are widespread and it is higher in the elderly and hospitalized population.[@ref9],[@ref10] Studies from Saudi Arabia revealed a varying prevalence of vitamin D deficiency (50-100%) in all age groups.[@ref11]-[@ref14] This high variability of prevalence in the same ethnic group raises the questions of reliability and accuracy of the 25-OHD assays used. With the recognized epidemic of hypovitaminosis D worldwide, it became imperative to accurately assess circulating levels of 25-OHD. However, the issue of substantial variability among different assays make clinical assessment of the vitamin D status of an individual patient problematic.[@ref15],[@ref16] Binkley et al[@ref17] reported that it is less appreciated that the assays, which are used to measure levels of 25-OHD may yield discrepant results, and they were the first to drew attention of the clinical community to the large variability in 25-OHD results both between methods and between laboratories. Several assays are being used for the measurement of vitamin D in serum or plasma including competitive binding assay, different manual and automated immunoassays, high-performance liquid chromatography (HPLC), and the lately developed liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay, which was found to be the most accurate and is currently considered the gold standard method for the assessment of 25OHD level.[@ref18],[@ref19] King Fahd Hospital of the University, Al-Khobar, Saudi Arabia laboratory uses the chemiluminescence immunoassay (CLIA) method to assess levels of 25-OHD, and we hypothesized that such an assay is overestimating the prevalence of hypovitaminosis D. The objective of this study is to compare the performance of the CLIA assay method used at our hospital with the radio-immuno assay (RIA) and the LCMS/MS assay methods among a sample of the Saudi population.

Methods {#sec1-2}
=======

This cross-sectional study was carried out between January 2011 and December 2012 using a convenient available sample. The study protocol was approved by the ethical committee of the University of Dammam, Dammam, Saudi Arabia. The research was funded by the Deanship of Scientific Research University of Dammam, and as per University policy of the University, the study was carried out as per the principles of the Helsinki Declaration. Prior to collection of blood samples, a search of the data sources was made, which included the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews, EMBASE, MEDLINE, and the Science Citation Index, for different vitamin D assays and their reliability. All participants gave an informed consent to participate and to provide a blood sample. A total of 200 adult individuals consisting of 50 males and 150 females were recruited. Adult male and female Saudi patients aged 18 years or older who attended the orthopedic, endocrinology, or obstetrics-gynecology clinics during the study period were invited to participate. Exclusion criteria were as follow: the presence of organ failure or disease that affects vitamin D metabolism, use of vitamin D supplements, or use of medications that alter vitamin D metabolism and refusal to consent for the study. A data collection sheet was used to collect information such as age, gender, disease conditions, medications used, dietary habits, and history of osteoporosis or fracture.

Biochemical analyses {#sec2-1}
--------------------

Venous blood samples were collected after an overnight fast for the assessment of serum calcium, phosphorus, alkaline phosphatase, parathormone, and 25-OHD levels. Vitamin D samples were protected from light and stored at -20°C until analysis. Measurements of 25-OHD level were performed using a 3 different assay methods.

Chemiluminescence immunoassay {#sec2-2}
-----------------------------

Chemiluminescence immunoassay was carried out by the Department of Special Clinical Chemistry at King Fahd Hospital of the University, Al-Khobar using DiaSorin (Liaison®, Saluggia, Italy) analyzer. During the first incubation, 25-OHD was dissociated from the binding protein and was binded to the specific antibody on the solid phase. At the end of 10 minutes, vitamin D that linked to the tracer was added and incubated for another 10 minutes. The unbound tracer was washed and the starter reagents were added to initiate the chemiluminescence reaction. The light signal was measured by photomultiplier as relative light units (RLU) and was inversely proportional to the concentration of 25OHD present in calibrator control, or study sample. Chemiluminescence immunoassay is a direct competitive CIA for quantitative determination of total 25-OHD in serum. It is a popular assay method and accounted for 36% of the sample returned during the year 2009 carried out by the External Quality Assessment Scheme for vitamin D metabolites (DEQAS).[@ref20] The sample analysis during the year 2012 carried out by the DEQAS revealed run-to-run coefficients of variation (CVs) in the range of 9.6-13.7%.[@ref21]

Radio-immuno assay {#sec2-3}
------------------

Plasma samples were analyzed using Gamma-B, 25-hydroxyvitamin D RIA (IDS, Boldon, UK) according to the manufacturer's instructions. Briefly, after following centrifugation a proportion of the supernatant were incubated with ^125^I-labelled 25-OHD tracer and sheep antibody to 25-OHD. Antibody-bound ^125^I-labelled 25-OHD was separated using antisheep IgG cellulose followed by centrifugation and decanting. Concentration of 25-OHD is inversely proportional to the bound radioactivity. To establish analytic quality standards, controls and samples were analyzed in duplicate and any sample with a coefficient of variation of \>10% were reanalyzed for confirmation. The control samples provided by the manufacturer were within the recommended range. The intra-assay precision was \<7% and the inter-assay precision was \<9% with sensitivity of -3 nmol/L.

Liquid chromatography-tandem mass spectrometry {#sec2-4}
----------------------------------------------

The third method used to measure 25-OHD levels in this study was LC-MS/MS, which was carried out at the Quest Diagnostics, Lab One, Ohio, USA using an API 3000 triple-quadrupole mass spectrometer (Applied Biosystems/MDS Sciex, AB Framingham, MA, USA) following the guidelines by the US National Institute of Standards and Technology (NIST). Sample analysis was performed according to the manufacturer's instructions. Briefly, initial extraction was carried out via protein precipitation followed by separation using the HPLC method, then, detection and quantification was carried out via tandem mass spectrometry. Concentration of both 25-OHD~3~ and 25-OHD~2~ were used to calculate the total 25-OHD levels. Analytical sensitivity was 4ng/ml and the reportable range for total 25-OHD was 4-1024ng/ml.

Statistical analysis {#sec2-5}
--------------------

Regression analysis and Bland-Altman plots were used for comparison between assays. Bland-Altman plots were also used to identify mean bias and the 95% limits of agreement between assays. Vitamin D level was classified as follows: vitamin D sufficiency defined as 25OHD level of ≥75 nmol/L (≥30ng/mL), insufficiency as 50-75nmol/L (20-30ng/mL), and deficiency as ≤50nmol/L (≤20ng/mL). Statistical analysis was performed using the Statistical Package for Social Sciences software, version 14.0 (SPSS Inc, Chicago, IL, USA). Data was presented as a mean±standard deviation (SD). The mean serum 25-OHD values with 95% confidence intervals (CI) for each assay results were calculated, and a *p*-value of \<0.05 was considered as significant.

Results {#sec1-3}
=======

A total of 200 participants with an average age of 45.7±16.1 years, consisting of 50 males (48.1±17.1 years) and 150 females (44.8±15.7 years) were included. Baseline demographic data of the participants with the mean and ranges of their different variables is given in [**Table 1**](#T1){ref-type="table"}. The findings revealed a low inter-assay agreement regarding the level of 25-OHD ([**Figure 1**](#F1){ref-type="fig"}). The mean 25-OHD levels came to be highest for the LC-MS/MS (21.65ng/mL, 95% CI: 19.74-23.56), intermediate for the RIA (16.607 ng/mL, 95% CI: 14.87-18.32) and lowest for the CLIA (13.864 ng/mL, 95% CI 12.109-15.618) (*p*\<0.05). There were also considerable differences between the 3 methods in proportion of participants classified as having low vitamin D. Using a 30mg/mL as a cut-off value for normal 25OHD, 6% were found to have normal levels using CLIA, 9% using RIA, and 22% using LCMS/MS. Analysis also showed that 57.3% of subjects had vitamin D deficiency using the LCMS/MS compared with 80.8% using the CLIA. Linear regression analysis was used to analyze the relationship between absolute differences in serum values between the methods against the mean of the 2 values in order to assess the variability at different serum level of 25OHD. The result revealed that beta coefficient of the regression of difference in CLIA versus RIA on mean of CLIA versus RIA was significant, beta coefficient of the regression of difference in CLIA versus LC-MS/MS on mean of CLIA versus LC-MS/MS was significant, and the beta coefficient of the regression of difference in RIA versus LC-MS/MS on mean of RIA versus LC-MS/MS was also significant ([**Table 2**](#T2){ref-type="table"}). The estimated parameters were negative and there were no statistically significant differences found, which indicates that the difference in variation between the methods were higher while the serum 25OHD level decreases ([**Table 2**](#T2){ref-type="table"}). The correlation of CLIA with LC-MS/MS was low (R^2^=0.53), which is much lower than the correlation between RIA and LC-MS/MS (R^2^=0.87). The correlation between CLIA and RIA is also very low (R^2^=0.46). The assay bias was evaluated using Bland-Altman plots (**Figures [2](#F2){ref-type="fig"}-[4](#F4){ref-type="fig"}**). The formula used to calculate the 95% CI was CI=mean ±1.96 SD. [**Figure 2**](#F2){ref-type="fig"} shows the bias between CLIA and RIA. The mean bias for CLIA-RIA is +20.2 with upper limit of 57.0 and lower limit of -16.7. The mean value lies between the upper and lower limit. The bias between CLIA and LCMS/MS is shown in [**Figure 3**](#F3){ref-type="fig"}. The mean bias for CLIA-LCMS/MS was +27.7 with upper limit of 68.5 and lower limit of -13.0. The mean value lies between the upper and lower limit, while the bias between RIA and LCMS/MS is shown in [**Figure 4**](#F4){ref-type="fig"}. The mean bias for RIA-LCMS/MS was +24.2 and the upper limit was 53.5 and the lower limit was -5.1.

###### 

Baseline characteristics and mean 25-hydroxyvitamin D values among 200 adults.
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###### 

Linear regression analyses for the relationship between the absolute differences in CLIA, RIA, and LCMS/MS against the mean of CLIA, RIA and LCMS/MS.
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![Bland-Altman plot for CLIA-LCMS/MS. CLIA - chemiluminescence immunoassay, LC-MS/MS - liquid chromatography-tandem mass spectrometry, HPLC - high performance liquid chromatography](SaudiMedJ-35-1243-g005){#F3}
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Discussion {#sec1-4}
==========

As a result of increased interest in the role of vitamin D in general health, the use of vitamin D testing has grown in recent years. Several assays have been developed for the measurement of vitamin D, and laboratories have started to use quick, easy, less time consuming, and less accurate automated assays instead of the more accurate but labor intensive methodology. Evaluation of the recently established automated assays showed variability of performance with wider CVs, inaccuracy of the results, failure to achieve minimal performance goals, poor cross-reactivity with 25-OHD~2~, and interference from heterophilic antibodies.[@ref21] This raised concerns regarding reliability of the reported results and the validity of inter-laboratory comparisons.[@ref20],[@ref22] DiaSorin (LIAISON®) vitamin D assay an automated CLIA methodology is the most commonly used commercial platform among laboratories participating in the DEQAS.[@ref23] The manufacturer's kit insert suggests a recovery of 100% for 25-OHD~3~ and 75% for 25-OHD~2~; however, DEQAS reported in 2005 a recovery of 54.2% for 25-OHD~3~ and 29.1% for 25-OHD~2~.[@ref24] The CLIA is also the only method used by most of the laboratories in Saudi Arabia, and it is also the method used at our hospital to assess vitamin D status. In this study, we observed high variability between CLIA, RIA, and LC-MS/MS assays. The mean 25-OHD level for the study population reported by CLIA was significantly lower than the mean 25-OHD level reported by LC-MS/MS (13.86±12.65ng/ml versus 21.65±13.7ng/ml) and it was significantly lower than the reported level by RIA methodology. Although this study was not designed to evaluate the prevalence of hypovitaminosis D, we found that the number of subjects with normal vitamin D level was the highest when using the LC-MS/MS assay method and the number of subjects diagnosed with vitamin D deficiency by CLIA method was higher than the number of subjects diagnosed by LC-MS/MS (80.8% versus 57.3%), which indicates that the CLIA method clearly overestimates the number of individuals with 25-OHD concentration \<50nmol/L (\<20ng/ml) as compared with the LC-MS/MS assay method. The LC-MS/MS is currently considered the best method for evaluation of 25-OHD levels because to the extract procedure ensures that both free and protein bound 25-OHD are quantified, and it can separate and accurately quantitate both 25-OHD~2~ and 25-OHD~3~.[@ref25] Several studies used the LC-MS/MS as the gold standard method during evaluation of other assay procedures.[@ref26]-[@ref28] However, the instrument is expensive and the systems require specialized expertise.

The precision for CLIA assay was reported by Harrison et al[@ref29] to be consistently poor. Moon et al[@ref27] found that the number of subjects with 25-OHD concentration \<50 nmol/L by LC-MS/MS was 44.6% compared with 52.2% by CLIA (LIAISON®). Snellman et al[@ref29] on reported 204 twins, and found that 8% of the subjects were insufficient using HPLC-APCI-MS, 22% by RIA and 43% by CLIA. While, Lai et al[@ref30] studied 813 patients used DiaSorin (LIAISON®) analyzer for CLIA at 2 different laboratories (laboratories A and B) and found that 46% (355/765) were classified as vitamin D deficient using CLIA compared with 17% (128/765) using LC-MS/MS at laboratory A, and 36% (76/209) versus 20% (41/209) for laboratory B indicating that one in 3 patients who were tested were misclassified by CLIA methodology as having deficiency of vitamin D. Their findings also indicated that the variability in vitamin D level is existing not only between assays, also between laboratories. Within assay and between assay variability in measurements of 25-OHD levels were also reported by previous studies.[@ref31],[@ref32] Linear regression analysis from this study revealed that parameters estimates are negative and highly statistically significantly different from zero, which indicates that the difference in variation between the methods were higher as the serum 25-OHD level decreases, and as most of our patients had low 25OHD levels, the variations is exaggerated. Contrary to our findings, Snellman et al[@ref29] found the parameters estimate to be positive, and in their study the difference in variation between the methods were higher as the serum 25OHD levels increase. We also found poor correlation between CLIA and both RIA (R^2^=0.46) and LC-MS/MS (R^2^=0.53) and, which is different from the finding of other studies where there was an acceptable correlation between CLIA and LC-MS/MS (0.9455).[@ref28] Similar to the study conducted by Farrell et al[@ref26] we found positive bias when comparing CLIA and RIA with LC-MS/MS. Holmes et al[@ref31] found positive bias between CLIA and LC-MS/MS, but negative bias between RIA and LC-MS/MS. Whereas Moon et al[@ref27] found negative bias of -13.5% when they compared CLIA with LC-MS/MS. The presence of bias may justify assay specific decision limits and calls for the standardization of the methods used to assess vitamin D and its metabolites.[@ref21],[@ref32],[@ref33] We recommend the standardization of assays should also be implemented in Saudi Arabia.

Our findings suggest that commonly used immunoassays for evaluation of vitamin D status can lead to under-estimation of vitamin D level with over-diagnosing of hypovitaminosis D. The high reported prevalence of vitamin D deficiency in our community is possibly related to the use of such imprecise assays. This implies that some of the patients may be treated inappropriately as the treatment decisions are likely to be influenced substantially by the 25-OHD assay being used.

There are several implications that arise from this study and cannot be ignored. It appears that the assays used to diagnose vitamin D levels, in most if not all over the country, is incorrect and based on these results patients are treated. Due to this fact we urge the medical fraternity to conduct similar studies to ours and make recommendations to appropriate authorities to streamline the diagnostic procedures for vitamin D assessment.

The strength of this study arises from the fact that we compared the commonly used immunoassays with the gold standard method in Saudi Arabia where the prevalence of vitamin D deficiency was reported to be high. However, our study has some limitations including the small sample size, being non-randomized and hospital based, in addition to the fact that not all assays were carried out at a local laboratory.

In conclusion, recently there has been increased interest in the relevance for vitamin D to human heath accompanied by increase demand of vitamin D testing that has led to the use of less precise assays. We found a large variation between the results of the 3 studied assays and the use of CLIA led to underestimation of the vitamin D level and overestimation of the number of subjects with low vitamin D level. We recommend the use of the gold standard LC-MS/MS assay, and we call for a large national community based study of the prevalence of low vitamin D using the gold standard method.

**Disclosure.** This study was funded by the Deanship of Scientific Research at the University of Dammam, Dammam, Saudi Arabia (Grant \# 2012087).
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